The effect of topical bevacizumab on corneal neovascularization
- PMID: 18439681
- DOI: 10.1016/j.ophtha.2008.02.013
The effect of topical bevacizumab on corneal neovascularization
Abstract
Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
Design: Prospective, nonrandomized, masked observational case series.
Participants: Ten eyes of 7 patients with corneal NV.
Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
Main outcome measures: Corneal NV and changes in ophthalmic evaluations.
Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Comment in
-
Bevacizumab for corneal neovascularization.Ophthalmology. 2009 Mar;116(3):592-3; author reply 593-4. doi: 10.1016/j.ophtha.2008.10.011. Ophthalmology. 2009. PMID: 19264217 No abstract available.
Similar articles
-
Bevacizumab for corneal neovascularization.Ophthalmology. 2009 Mar;116(3):592-3; author reply 593-4. doi: 10.1016/j.ophtha.2008.10.011. Ophthalmology. 2009. PMID: 19264217 No abstract available.
-
Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.Cornea. 2009 Oct;28(9):1070-3. doi: 10.1097/ICO.0b013e31819839f9. Cornea. 2009. PMID: 19724199
-
Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.Acta Ophthalmol. 2009 Sep;87(6):653-8. doi: 10.1111/j.1755-3768.2008.01399.x. Epub 2008 Nov 18. Acta Ophthalmol. 2009. PMID: 19021596
-
Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis.Cornea. 2013 Apr;32(4):435-44. doi: 10.1097/ICO.0b013e3182542613. Cornea. 2013. PMID: 22668582 Review.
-
[Topical inhibition of angiogenesis at the cornea. Safety and efficacy].Ophthalmologe. 2009 May;106(5):399-406. doi: 10.1007/s00347-009-1934-0. Ophthalmologe. 2009. PMID: 19396447 Review. German.
Cited by
-
Attenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complication.Int J Ophthalmol. 2016 Sep 18;9(9):1255-9. doi: 10.18240/ijo.2016.09.03. eCollection 2016. Int J Ophthalmol. 2016. PMID: 27672587 Free PMC article.
-
Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.Clin Ophthalmol. 2016 Jun 27;10:1167-74. doi: 10.2147/OPTH.S103443. eCollection 2016. Clin Ophthalmol. 2016. PMID: 27418802 Free PMC article.
-
Corneal nerves in health and disease.Surv Ophthalmol. 2014 May-Jun;59(3):263-85. doi: 10.1016/j.survophthal.2013.09.002. Epub 2014 Jan 23. Surv Ophthalmol. 2014. PMID: 24461367 Free PMC article. Review.
-
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Saudi J Ophthalmol. 2017 Apr-Jun;31(2):99-105. doi: 10.1016/j.sjopt.2017.02.008. Epub 2017 Mar 8. Saudi J Ophthalmol. 2017. PMID: 28559722 Free PMC article. Review.
-
[Pterygium. Etiology, clinical aspects and novel adjuvant therapies].Ophthalmologe. 2010 Jun;107(6):517-20, 522-4. doi: 10.1007/s00347-009-2100-4. Ophthalmologe. 2010. PMID: 20393732 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
